Budapest, June 3, 2022 - GI.HU Ltd.
A population-specific vaccine for higher
efficacy.
After long-term research and
development, Genetic Immunity aligned its strategic plan to perform a Phase 3 clinical
trial and successfully constructed a plasmid (p) DNA vaccine for human immunodeficiency
virus (HIV) specific for the Eastern European and Middle-Asian population. The active
pharmaceutical ingredient's appropriate design is based on the sequence database of HIV
patients. The genetic distance between the pDNA construct and the HIV sequences
circulating in the targeted population is not higher than the intrapopulation
variability. The aim of this vaccination strategy is to boost the anti-HIV immune
response of the patient. The specific DNA is delivered to dendritic cells through the
skin. Besides the novel DNA-based vaccination strategy, the non-invasive form of
application is also unique in both the vaccination and the HIV fields. Our clinical
trial group is working to make the treatment feasible within a year and a half.
